For US health care professionals
For postmenopausal women with hormonereceptor-positive metastatic breast cancer withdisease progression following antiestrogen therapy
FASLODEX is indicated for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
Prescribing Information with Patient Information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.
This product information is intended for US health care professionals only.
FASLODEX is a registered trademark of the AstraZeneca group of companies.
©2013 MedImmune, Specialty Care Division of AstraZeneca. All rights reserved. 407003-1402300 Last Updated 8/13